A mid-stage trial of EloraTZP showed weight loss of up to 23.3%, but up to 27% of patients stopped treatment.
Eli Lilly is trying to beat its own best-selling obesity drug, and a mid-stage trial suggests it can, at a price.
In a Phase 2b study of 367 patients over 48 weeks, Lilly's experimental therapy, EloraTZP, produced weight loss of up to 23.3%. Patients taking the 15-milligram dose of tirzepatide, the active ingredient in Zepbound and Mounjaro, lost 14.8%. Lilly plans to begin Phase 3 trials in the fourth quarter of 2026.
The stock rose as much as 2.6% on the news before settling about 0.5% higher.
The size of the edge
The efficacy gap is substantial. At the top of its range, EloraTZP delivered 8.5 percentage points more weight loss than tirzepatide, or about 57% more in relative terms. In a market where the leading therapies already produce double-digit results, an improvement of that size could define the next generation of treatment.
The cost of the edge
The tolerability data temper the result. Between 10.8% and 27.0% of patients on EloraTZP discontinued treatment, depending on the dose, compared with 2.9% on tirzepatide alone. At the high end, patients on EloraTZP stopped at more than nine times the rate of those on the existing drug.
That ratio is the central question for the program. Obesity drugs are taken for years, and a therapy that more patients abandon delivers less real-world weight loss than its trial results suggest. Payers, already wary of the cost of these medications, will weigh persistence as heavily as peak efficacy.
Why the muted stock reaction makes sense
Investors appear to have priced both halves of the result. A drug that delivers meaningfully more weight loss than tirzepatide extends Lilly's franchise and widens the gap with competitors. But a discontinuation rate that high raises the risk that Phase 3 trials will need lower or slower-titrated doses, which could narrow the efficacy advantage.
The strategic logic
For Lilly, the program is a defensive as well as offensive move. Tirzepatide is the company's growth engine, and a successor that outperforms it lets Lilly compete with its own success rather than ceding the next step to a rival. The Phase 3 design, particularly how it manages dose escalation, will reveal how the company plans to close the tolerability gap.
What to watch
The start of Phase 3 in the fourth quarter is the next milestone. Any disclosure of the trial's dosing strategy will indicate whether Lilly is prioritizing maximum weight loss or a profile closer to tirzepatide's tolerability.